• 740 Y-P: Precision PI 3-Kinase Activator for Cell Signaling

  2026-08-04

  740 Y-P enables researchers to reliably activate the PI3K/AKT pathway, facilitating advanced vesicular trafficking, apoptosis, and neuronal survival assays. With clear protocol guidance and troubleshooting tips, this reagent from APExBIO powers reproducible, high-clarity cell signaling experiments.

• Fluorinated CXCR4 Inhibitor A1 Surpasses AMD3100 in Colorect

  2026-08-03

  Khorramdelazad et al. introduce A1, a novel fluorinated CXCR4 inhibitor, demonstrating its superior efficacy over AMD3100 (plerixafor) in inhibiting colorectal cancer progression and modulating the tumor microenvironment. Their integrative study showcases A1's potential as an advanced tool for cancer metastasis inhibition and immune modulation in preclinical CRC models.

• Methyl-β-cyclodextrin: Technical Guidance for Membrane Studi

  2026-08-03

  Methyl-β-cyclodextrin is used to extract cholesterol and modulate membrane fluidity in cell-based and biochemical assays. It is designed for research workflows involving membrane lipid organization and cholesterol-sensitive processes, not for diagnostic or clinical use. Strict attention to solubility, storage, and workflow-specific handling is needed to maintain reagent performance.

• QX77: Molecular Chaperone Activator for Autophagy Modulation

  2026-08-02

  QX77 is a molecular chaperone activator that upregulates LAMP2A and Rab11, enhancing chaperone-mediated autophagy in cellular models. It inhibits embryonic stem cell self-renewal and promotes differentiation, making it a valuable tool for autophagy pathway modulation. QX77 is supplied by APExBIO for research use only, with validated storage and workflow guidelines.

• AZD8055: Technical Parameters and Best Practices for mTOR In

  2026-08-01

  AZD8055 is a potent, highly selective mTOR inhibitor optimized for preclinical research dissecting mTORC1 and mTORC2 signaling. It is best suited for mechanistic studies in cancer biology, metabolism, and signal transduction, but is not recommended for projects focused on clinical efficacy or requiring water-soluble compounds. Proper handling, solubility management, and workflow design are essential for reproducible results.

• Prion-Based Protein Self-Assembly Drives Adaptive Mutagenesi

  2026-07-31

  This study uncovers how prion-induced self-assembly of DNA repair proteins in yeast acts as a heritable, reversible switch for mutagenesis, enabling rapid adaptation to environmental stress. The findings highlight a previously underappreciated epigenetic mechanism for tuning genome diversification and have broad implications for understanding drug resistance and evolutionary dynamics.

• LKB1 Inhibits Telomerase via Histone Lactylation in Lung Ade

  2026-07-31

  This study uncovers a mechanistic link between LKB1 function and the repression of telomerase activity in lung adenocarcinoma, mediated by changes in histone lactylation and transcriptional regulation. The findings offer a new cellular senescence pathway and highlight targets for potential therapeutic intervention in LKB1-deficient cancers.

• Ranolazine in Cardiac Ischemia Research: Applied Workflows &

  2026-07-30

  Ranolazine’s dual action as an anti-ischemic agent empowers metabolic and electrophysiological modeling in cardiac ischemia research, enabling advanced experimental control. This guide delivers practical workflow enhancements, troubleshooting strategies, and insights linking metabolic modulation to emerging immunometabolic and autophagy research.

• Preclinical Advances in Anlotinib: Potent Multi-Target TKI f

  2026-07-30

  This article reviews the preclinical characterization of Anlotinib hydrochloride as a highly potent and selective multi-target tyrosine kinase inhibitor, with a focus on its inhibitory effects on VEGFR2-mediated angiogenesis in cancer models. The findings highlight Anlotinib's superior efficacy and selectivity profile, offering practical insights for researchers designing angiogenesis and migration assays.

• Network Pharmacology Identifies Apigenin as an Anti-Alzheime

  2026-07-29

  A recent network medicine study systematically identified Apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one) as a leading flavonoid candidate for Alzheimer’s disease intervention. Through both computational and experimental approaches, the study elucidates Apigenin’s neuroprotective and anti-inflammatory mechanisms, highlighting its translational potential for neurodegeneration research.

• Strategic SAHH Inhibition: Advancing Fibrosis & Methylation

  2026-07-29

  This thought-leadership article explores the mechanistic and translational importance of 3-Deazaadenosine hydrochloride as a selective S-adenosylhomocysteine hydrolase inhibitor in hepatic fibrosis research. By bridging recent discoveries in m6A-mediated mRNA regulation—specifically the IGF2BP1/TUBB4B/FAK axis—with practical guidance for experimental workflows, the article delivers actionable insights for translational researchers. Enhanced by evidence links, protocol parameters, and a critical outlook, it positions APExBIO’s high-purity reagent as a cornerstone for next-generation studies in methylation, inflammation, and cell proliferation.

• Batimastat (BB-94): Advanced MMP Inhibition for Synaptic and

  2026-07-28

  Explore Batimastat (BB-94) as a precise, broad-spectrum MMP inhibitor for dissecting matrix remodeling in both tumor and synaptic contexts. This article offers in-depth analysis and practical guidance for leveraging BB-94 in innovative research applications.

• FXR-KLF11 Axis Suppresses JAK2/STAT3 in Contrast-Induced AKI

  2026-07-28

  This study delineates how FXR activation upregulates KLF11, suppressing the JAK2/STAT3 pathway to mitigate contrast-induced acute kidney injury (CI-AKI). These findings advance the understanding of CI-AKI pathogenesis and highlight new preventive strategies targeting inflammation and apoptosis in renal tissue.

• Targeted CRISPRi Delivery to Adipocytes for Metabolic Diseas

  2026-07-27

  This study demonstrates a targeted, nonviral CRISPR interference (CRISPRi) system for silencing Fabp4 in white adipocytes, resulting in significant improvements in obesity, inflammation, hepatic steatosis, and insulin resistance in vivo. The findings highlight the therapeutic promise of adipocyte-specific gene modulation for metabolic disease research and provide a technical foundation for future hepatoprotective and metabolic studies.

• Gramine Induces Ferroptosis in TNBC via CUL3–MTDH Ubiquitina

  2026-07-27

  This study reveals that gramine suppresses triple-negative breast cancer (TNBC) by inducing ferroptosis through the CUL3–MTDH ubiquitination axis. The findings provide a mechanistic framework for ferroptosis-based therapies and inform future proteomic research in aggressive breast cancer subtypes.

450 records 9/30 page Previous Next First page 上5页 678910 下5页 Last page